- recruitingPHASE1
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
This study is testing a new medicine called MOv18 IgE for women with advanced ovarian, endometrial, or triple-negative breast cancer. It aims to find a safe dose and see how well it works, especially in cancers that have a specific marker called Folate Receptor Alpha.
United Kingdom - recruitingPHASE1
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This study is testing a new drug, CTIM-76, for some difficult-to-treat cancers like ovarian, testicular, and endometrial cancer. It's an early-stage study to check for safety and find the right dose. The drug works by helping your immune system fight the cancer.
United States · United Kingdom - active not recruitingPHASE3
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This study is testing a new drug called Rina-S for platinum-resistant ovarian cancer. It compares Rina-S to standard chemotherapy treatments. You have an equal chance of receiving Rina-S or a standard chemotherapy. All participants receive active treatment, no placebo.
United States · Australia · Austria - recruitingPHASE2
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
This study is testing a new medicine called lorigerlimab for some women with advanced ovarian or gynaecological cancers that have not responded well to certain other treatments. The aim is to see if it's safe and helps shrink the cancer.
United States · Canada · South Korea - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom